Skip to main content
Shandong Lukang Pharmaceutical Co.,Ltd. logo

Shandong Lukang Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 600789 ISIN · CNE000000P61 LEI · 300300Z0XHZI7D4MKT83 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,533 across all filing types
Latest filing 2026-05-29 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600789

About Shandong Lukang Pharmaceutical Co.,Ltd.

https://en.lkpc.com/

Shandong Lukang Pharmaceutical Co., Ltd. is a large-scale enterprise specializing in the research, development, and manufacturing of a wide range of medical and veterinary products. The company is a major producer of antibiotics, with a product portfolio that includes penicillin, cephalosporins, aminoglycosides, and various semi-synthetic antibiotics. Its operations span the entire production chain, from pharmaceutical intermediates and active pharmaceutical ingredients (APIs) to finished dosage forms. In addition to human medicine, the company maintains a significant presence in the veterinary drug market and the production of amino acids. Utilizing advanced fermentation and chemical synthesis technologies, the company serves both domestic and international markets, focusing on high-quality standards and large-scale industrial output to meet global healthcare demands.

Recent filings

Filing Released Lang Actions
北京市通商律师事务所关于山东鲁抗医药股份有限公司2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a legal opinion (“法律意见书”) from a law firm concerning the procedures, attendance and vote results of the company’s 2025 Annual General Meeting. It contains detailed voting results for each resolution, matching the definition of “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-05-29 Chinese
鲁抗医药2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is an announcement of the resolutions passed at the 2025 Annual General Meeting, including detailed vote counts and outcomes for each agenda item. This matches the definition of “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-05-29 Chinese
鲁抗医药2025年年度股东会会议材料
AGM Information Classification · 84% confidence The document consists of the full set of materials for the 2025 Annual General Meeting (AGM) of Shandong Lukang Pharmaceutical Co., Ltd., including meeting notices, attendance instructions, detailed agenda, board work report, profit distribution proposal, auditor appointment proposal, and various other shareholder resolutions. It is not merely an announcement of a report nor a proxy statement, but the actual meeting materials to be presented at the AGM. According to the filing definitions, this falls under AGM Information (Code: AGM-R).
2026-05-20 Chinese
鲁抗医药2025年度独立董事述职报告（綦好东）
Board/Management Information Classification · 95% confidence The document is titled '2025年度独立董事述职报告' which translates to '2025 Independent Director's Work Report'. It is a detailed report by an independent director about their duties, attendance, and activities during the year 2025. The content focuses on the director's responsibilities, attendance at meetings, communication with shareholders, audit committee activities, and overall evaluation of their role. It does not contain financial statements or financial performance data, nor is it an announcement or a brief summary. It is a specific report on the independent director's work and governance role, which fits best under Board/Management Information (MANG) as it relates to management and board-level reporting rather than financial results or audit reports. The document length is 3385 characters, which is relatively short but contains substantive content about board/management activities rather than just an announcement or certification. Therefore, the classification is MANG with high confidence.
2026-04-24 Chinese
鲁抗医药关于2025年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the company's fundraising activities, specifically the storage, management, and actual use of funds raised through a specific stock issuance in 2025. It includes detailed financial tables about the amount raised, usage, bank accounts, and compliance with regulatory requirements. The document references regulatory approvals and audit reports related to the fundraising. It is not an announcement of a report but the report itself, containing substantive financial data and analysis about the fundraising and its use. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2026-04-24 Chinese
600789_2025年_年度报告
Annual Report Classification · 100% confidence The document is titled "山东鲁抗医药股份有限公司2025年年度报告" which translates to "Shandong Lukang Pharmaceutical Co., Ltd. 2025 Annual Report." It contains detailed financial data for the year 2025, including profit and loss statements, cash flow, balance sheet data, management discussion and analysis, company overview, industry analysis, and other comprehensive information typical of an annual report. The document includes audited financial statements with auditor's opinion, management certifications, detailed financial metrics, and extensive narrative sections on business operations, industry conditions, and company strategy. The length of the document (15,000 characters) and the depth of content confirm it is the full annual report rather than an announcement or summary. Therefore, the appropriate classification is Annual Report (10-K). FY 2025
2026-04-24 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.